HF-158K1 by HighField Biopharmaceuticals for Pancreatic Cancer: Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Pancreatic Cancer.

Ministers of Health commit to accelerated action against malaria in Africa

Ministers of Health from African countries with the highest burden of malaria committed today to accelerated action to end deaths from the disease.

April 1, 2024

Bacterial toxin may fuel colorectal cancer metastasis

A toxin in the bacteria that’s one of the most common causes of foodborne illness accelerates the spread of colorectal tumors to other parts of

December 7, 2024

Greenlane Regains Compliance with Nasdaq Listing Requirements

BOCA RATON, FL / ACCESSWIRE / June 22, 2023 / Greenlane Holdings, Inc. (Nasdaq:GNLN) (“Greenlane”), one of the largest global sellers of premium cannabis accessories,

June 23, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.